The Affordable Healthcare Act's Effect of Biopharma Innovation

February 14, 2014
The Pharm Exec staff

Pharmaceutical Executive

The Affordable Care Act (ACA) has sent biopharmaceutical companies scrambling to understand how their business model, including its ability to innovate, will change as healthcare reform moves forward.

The Affordable Care Act (ACA) has sent biopharmaceutical companies scrambling to understand how their business model, including its ability to innovate, will change as healthcare reform moves forward. Within this uncertain market, what is obvious is that the industry is in the midst of significant transition. Critical drivers of this change are largely macroeconomic; policy is simply accelerating change. Understanding this backdrop is crucial as the biopharmaceutical industry contemplates product innovation within the changing landscape of healthcare in the United States.

This article by Jill E. Sackman, Rita E. Numerof, and Michael Abrams looks at the impact of shifting risk, and how industry can innovate in the changing US healthcare landscape.